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Blocking the apoE/Aβ interaction ameliorates
Aβ-related pathology in APOE ε2 and ε4 targeted
replacement Alzheimer model mice
Joanna E Pankiewicz1,3, Maitea Guridi1, Jungsu Kim4,5,6,7, Ayodeji A Asuni1, Sandrine Sanchez1, Patrick M Sullivan8,9,
David M Holtzman4,5,6 and Martin J Sadowski1,2,3,10*

Abstract
Accumulation of β-amyloid (Aβ) in the brain is essential to Alzheimer’s disease (AD) pathogenesis. Carriers of the
apolipoprotein E (APOE) ε4 allele demonstrate greatly increased AD risk and enhanced brain Aβ deposition. In
contrast, APOE ε2 allele carries show reduced AD risk, later age of disease onset, and lesser Aβ accumulation.
However, it remains elusive whether the apoE2 isoform exerts truly protective effect against Aβ pathology or
apoE2 plays deleterious role albeit less pronounced than the apoE4 isoform. Here, we characterized APPSW/PS1dE9/
APOE ε2-TR (APP/E2) and APPSW/PS1dE9/APOE ε4-TR (APP/E4) mice, with targeted replacement (TR) of the murine Apoe
for human ε2 or ε4 alleles, and used these models to investigate effects of pharmacological inhibition of the apoE/Aβ
interaction on Aβ deposition and neuritic degeneration. APP/E2 and APP/E4 mice replicate differential effect of human
apoE isoforms on Aβ pathology with APP/E4 mice showing a several-fold greater load of Aβ plaques, insoluble brain
Aβ levels, Aβ oligomers, and density of neuritic plaques than APP/E2 mice. Furthermore, APP/E4 mice, but not APP/E2
mice, exhibit memory impairment on object recognition and radial arm maze tests. Between the age of 6 and 10
months APP/E2 and APP/E4 mice received treatment with Aβ12-28P, a non-toxic, synthetic peptide homologous to
the apoE binding motif within the Aβ sequence, which competitively blocks the apoE/Aβ interaction. In both
lines, the treatment significantly reduced brain Aβ accumulation, co-accumulation of apoE within Aβ plaques,
and neuritic degeneration, and prevented memory deficit in APP/E4 mice. These results indicate that both apoE2
and apoE4 isoforms contribute to Aβ deposition and future therapies targeting the apoE/Aβ interaction could
produce favorable outcome in APOE ε2 and ε4 allele carriers.
Keywords: Apolipoprotein E, Alzheimer’s disease, β-amyloid, Neurodegeneration, Therapy

Introduction
Alzheimer’s disease (AD) is a familial and sporadic neurodegenerative disease. Its neuropathological hallmarks
include parenchymal plaques and vascular deposits of
β-amyloid (Aβ), intraneuronal paired helical filaments
composed of hyperphosphorylated tau and ubiquitin,
widespread loss of synapses and neurons, and the appearance of reactive astrocytes and microglia. Converging
lines of evidence derived from genetic, neuropathological,
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biomarker, and transgenic animal studies implicate disturbance of Aβ homeostasis leading to its progressive
accumulation in the brain as a driving mechanism of AD
pathogenesis (reviewed in [1,2]). Aβ is a 39- to 43-residuelong hydrophobic peptide, which readily self-aggregates
into synaptotoxic oligomers and thioflavin-S (Th-S)-binding fibrils. Mutations in amyloid precursor protein (APP)
or presenilin (PS) 1 and 2 genes found in familial AD
cases increase total Aβ secretion or alter a ratio of Aβ1-40:
Aβ1-42 production, resulting in increased secretion of
the more toxic and aggregation-prone Aβ1-42 [1]. In the
far more prevalent sporadic AD, the mechanism(s)
underlying disturbance of Aβ homeostasis are less obvious,
but inheritance of the apolipoprotein (apo) E isoforms has
been thus far established by numerous independent studies
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as the strongest genetic factor modulating overall risk of
occurrence of the disease and age of onset (reviewed in
[3]). ApoE is a 34-kDa lipid carrier protein, which in the
brain is produced by astrocytes and secreted as nascent,
high-density lipoprotein-like particles [4]. Three major
isoforms of apoE are encountered in humans, differing
by the occurrence of cysteine and arginine in positions
112 and 158: apoE2 (Cys112, Cys158), apoE3 (Cys112,
Arg158), and apoE4 (Arg112, Arg158). These single-aminoacid variations in the apoE sequence have serious effects
on its properties, with apoE2 having reduced binding
affinity for the low density lipoprotein (LDL) receptor [5]
and apoE4 exhibiting an intrinsic domain interaction
that alters its lipid-binding properties and results in an
increased risk of hyperlipidemia and atherosclerosis [4].
Inheritance of the APOE ε4 allele is the strongest
known risk factor for sporadic AD and shows directs
association with increased Aβ plaque load and reduced
age of disease onset [6-8]. Conversely, the APOE ε2
allele appears to delay, and reduce the relative risk of
developing AD and is associated with a lower burden of
Aβ deposits compared with the most common APOE
ε3 allele [9,10]. To provide a mechanistic explanation
for the variable effect of apoE isoforms on Aβ accumulation and overall disease risk, it has been proposed
that they produce a differential effect on Aβ clearance
and Aβ aggregation and deposition [3]. However, it
remains unclear whether the effect of apoE2 on Aβ
pathology is truly protective, or whether apoE2 merely
plays deleterious role albeit less pronounced than that
of apoE4. To exert its promoting effect on Aβ aggregation and brain deposition, apoE directly interacts with
Aβ, binding to its amino-acid residues 12–28 [11,12].
In this study, we analyzed long-term outcomes of the
pharmacological disruption of the apoE/Aβ interaction
in the background of apoE2 or apoE4, which show
differential effect on Aβ pathology and AD morbidity.
For this purpose we used APPSW/PS1dE9 AD transgenic
(Tg) model mice with targeted replacement (TR) of
both murine Apoe alleles with the human APOE ε2 or
APOE ε4 alleles, which continued to be expressed under
the control of the endogenous mouse Apoe promoter
[13]. As previously shown, human APOE alleles targeted
to APPSW/PS1dE9 mice reproduce their differential effect
on the magnitude of Aβ plaque load [13] but do not
delay onset of Aβ deposition compared to APPSW/PS1dE9
mice expressing native murine apoE [14]. Since these
APPSW/PS1dE9/APOE ε2-TR and APPSW/PS1dE9/APOE
ε4-TR lines (hereafter designated as APP/E2 and APP/E4;
respectively) are novel AD Tg animal models, their behavioral and biochemical characterization was undertaken
as a part of this study. To pharmacologically disrupt
the apoE/Aβ interaction, we used a previously characterized non-toxic, synthetic peptide Aβ12-28P, which is
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homologous to the apoE binding motif within the Aβ
sequence [12,13,15]. In Aβ12-28P, proline replaces valine
in the 18 position and the peptide was synthesized with
D-amino acids and end-protected for extended serum
half-life and increased BBB permeability [12]. Aβ12-28P
inhibits apoE4/Aβ binding with KI = 12.9 nM and neutralizes the promoting effect of apoE on Aβ fibrillization
in vitro, but has no effect on self-assembly of Aβ in the
absence of apoE [15]. Therefore, this study also evaluated
the prospects for disrupting the apoE/Aβ interaction in
human population diversified by the occurrence of various
APOE alleles.

Material and methods
Materials and reagents

Unless stated otherwise all reagents and antibodies were
purchased from Sigma-Aldrich (St. Louis, MO). Aβ1228P, Aβ1-40, and Aβ1-42 peptides were custom synthesized
and purified in the WM Keck Proteomic Facility of Yale
University (New Haven, CT) in the laboratory of Dr. James
I. Elliott as previously described [12,13].
Animals

All mouse care and experimental procedures were approved by Institutional Animal Care and Use Committees
of the New York University School of Medicine and the
Washington University School of Medicine. APP/E2 and
APP/E4 mice were generated by crossing-breeding of
APPSW/PS1dE9 mice [14] with APOE ε2-TR or APOE
ε4-TR mice [16,17] as previously described [13]. APOE
ε2-TR or APOE ε4-TR mice retain regulatory sequences
of the mouse Apoe gene and the noncoding murine
exon 1 surrounding the inserted human exons 2′, 3′,
and 4′ [17,18] and therefore, they express the human
apoE protein at physiological levels. Both lines were
maintained by mating APP/E2 and APP/E4 founders
with APOE ε2-TR and APOE ε4-TR animals, respectively.
Husbandry and genotyping was performed as previously
described [13]. Mice were maintained in a barrier facility
with a 12/12-h light/dark cycle and ad libitum food and
water access. Female APP/E2 and APP/E4 mice received
treatment with vehicle or Aβ12-28P from the age of 6
to 10 months. Aβ12-28P was diluted to 2 mg/mL in
sterile phosphate buffered saline at pH 7.4 directly before injections and intraperitoneally administered three
times a week (0.8 mg per injection). Vehicle treated mice
received injections with phosphate buffered saline only.
Immediately prior to concluding the study the animals
were subjected to behavioral testing conducted following
our published protocols [15,19,20]. Age and sex-matched
littermates of APP/E2 and APP/E4 mice in which genotyping was negative for the APPSW/PS1dE9 transgene
(hereafter designated as WT/E2 and WT/E4, respectively)
were used as an apoE isoform background control during
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the behavioral and serological testing. After concluding
the experiment, all animals were killed with an overdose
of sodium pentobarbital (150 mg/kg). The blood was
collected through a cardiac puncture and the serum was
separated by centrifugation. Animals were transcardially
perfused and their brains and internal organs collected for
histopathological analysis as previously described [15].
Histological processing, immunohistochemistry, and
unbiased morphometric analysis

Series of 40 μm-thick serial brain sections evenly spaced
every 400 μm along the entire rostro-caudal brain axis
were stained with Th-S to visualize fibrillar Aβ deposits,
with Gallyas silver stain to identify plaque-associated
neuritic dystrophy [21], or immunohistochemically with
monoclonal antibody (mAb) HJ3.4 raised against the Nterminus of Aβ (1:250) [13] or with mAb 3D12 (1:200)
raised against apoE (Novus Biologicals; Littleton, CO).
The intensity of HJ3.4 and 3D12 immunostaining was
enhanced by 10 min pretreatment with 44% formic acid
(FA) and the immunohistochemistry protocol was concluded using 3,3′-diaminobenzidine and Cy3, respectively.
The load of Th-S and 3D12 immunopositive amyloid plaques in the neocortex and hippocampus was determined
using unbiased sampling and automated image threshold
analysis, as previously described [13,15]. The density of
neuritic plaques was calculated by counting their total
number on all serial sections from a Gallyas stained series
and then dividing the number obtained by the cumulative
area of all the neocortical or hippocampal cross-sectional
profiles.
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Rockford, IL). The concentration of Aβ oligomers was
determined in the neat homogenate using a human
aggregated β-amyloid ELISA kit (Invitrogen, Carlsbad,
CA) [13].

ApoE ELISA

Sandwich ELISA for apoE was performed using mAb
3D12 (1:2,000) as the capture antibody and biotinylated goat anti-human apoE polyclonal antibody (1:2,500)
(Meridian Life Science, Inc.; Memphis, TN) as the detection
antibody. ApoE concentrations were quantified in DEA
and FA brain extracts. ELISA readouts were converted to
apoE concentrations using standard curves prepared from
recombinant human apoE2 or apoE4 (Leinco Technologies,
Inc., St. Louis, MO) and multiplied by all dilutions made
during DEA or FA extractions. The final brain apoE concentrations were reported in reference to the total brain
protein concentration.

Statistical analysis

RAM data were analyzed using one-way analysis of
variance (ANOVA) followed by the Newman-Keuls post
hoc test. All other data sets were compared using the
unpaired Student’s t test with Welch’s correction following confirmation of normal data distribution by the
Kolmogorov-Smirnov and Shapiro-Wilk tests. All statistical analyses were performed using GraphPad Prism
v5.04 (GraphPad Software, Inc., La Jolla, CA).

Aβ ELISA

Results

Cortical mantle and hippocampi were dissected out,
homogenized, and subjected to diethylamine (DEA) and
FA extractions as previously described [15]. Concentrations of Aβ peptides in DEA and FA brain extracts were
determined by sandwich ELISAs using mAbs HJ2 and
HJ7.4, which selectively discriminate between C-terminal
configuration of Aβx−40 and Aβx−42, respectively; as
coating antibodies (1 μg/well) [13] and biotinylated mAb
4G8 (1:2,000) (Covance; Princeton, NJ) directed against
Aβ residues 17–24 as the detection antibody [22,23]. Since
the N-terminal configuration of Aβ peptides measured by
ELISA remained uncharacterized we referred to them as
Aβx-40 and Aβx-42. ELISA readouts were converted to
actual peptide concentrations based on readouts from
standard curves prepared from FA-treated synthetic
Aβ1-40 and Aβ1-42 peptides and multiplied by all dilutions
made during DEA and FA extractions. Final values of
brain concentrations of Aβ peptides were reported in
reference to the total brain protein concentration, the
latter determined in a neat brain homogenate using
the bicinchoninic acid assay (Pierce Biotechnology Inc.;

Treatment of APP/E2 and APP/E4 mice with Aβ12-28P

Female APP/E2 and APP/E4 mice received Aβ12-28P or
vehicle through intraperitoneal injections from the age
of 6 to 10 months. The treatment commenced at the
start of Aβ plaque formation in these Tg lines. Veterinary
staff closely monitored the animals undergoing treatment
for any signs of toxicity. Monitoring parameters included
body weight, physical appearance, changes in coat appearance, occurrence of unprovoked behavior, and blunted
or exaggerated responses to external stimuli. APP/E2 and
APP/E4 mice receiving vehicle and Aβ12-28P showed
no differences in respect to those parameters compared
to their WT/E2 and WT/E4 age and sex-matched littermates, respectively. Measurements of the immune response
against Aβ in post-treatment sera of APP/E2 and APP/E4
mice showed no evidence of increased titer of anti-Aβ
antibodies in IgG and IgM classes associated with Aβ1228P treatment (Additional file 1: Figure S1A and B). This
observation indicates that treatment outcomes of Aβ1228P administration cannot be accounted for by an anti-Aβ
vaccination effect.
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Effect of Aβ12-28P treatment on serum cholesterol and
apoE levels

We also monitored the effect of Aβ12-28P treatment
on the serum cholesterol and apoE levels. Ten-monthold APP/E2 mice showed a 5.1-fold higher total serum
cholesterol level and a 13.2-fold higher serum apoE
level than APP/E4 mice (p < 0.001) (Additional file 1:
Figure S2A). These findings are consistent with type III
hyperlipoproteinemia, previously described in human
APOE ε2-TR mice [17]. Compared to the vehicle control
mice, Aβ12-28P treatment was associated with a reduction of the total serum cholesterol level by 15.7% in APP/
E2 animals and by 33.3% in APP/E4 animals (p < 0.05)
(Additional file 1: Figure S2A). In addition, the total serum
apoE level showed a mild but insignificant reduction
with Aβ12-28P treatment in both APP/E2 and APP/E4
mice (Additional file 1: Figure S2B). Consistently with
our previously published observations [15] these results
indicate that Aβ12-28P exerts an effect on serum cholesterol metabolism in addition to targeting the apoE/Aβ
interaction in the brain.
Behavioral studies

The performance of vehicle- and Aβ12-28P-treated APP/
E2 and APP/E4 mice was compared to those of sex
and age matched WT/E2 and WT/E4 littermates,
which received no treatment. Behavioral testing included
the object recognition test (ORT), which tests animals’
long-term recognition memory, followed by the radial arm
maze (RAM), which is a test of animals’ spatial working
memory. Behavioral studies were conducted during the
last 3 weeks of the treatment experiment and during the
testing mice continued to receive vehicle or Aβ12-28P
injections. During the acquisition session of the ORT,
when the animals are allowed to explore freely the two
identical objects presented in the testing arena, WT/E2,
and vehicle- and Aβ12-28P-treated APP/E2 mice, equally
interacted with both objects as expected of normal mice
(data not shown). Following a 3-h interval, which the mice
spent in their home cages, one of the two familiar objects
was replaced with a novel one, and the behavior of the
mice was then observed during the retention session.
All three tested mice groups spent significantly more
time exploring the novel object than the familiar one
during the retention session (Figure 1A), consistent
with normal rodent exploratory behavior. WT/E4 mice,
and vehicle- and Aβ12-28P-treated APP/E4 mice, also
interacted equally with two identical objects during the
ORT acquisition session (data not shown). However,
during the retention session, WT/E4 mice and Aβ1228P-treated APP/E4 mice spent significantly more time
exploring the novel object, while vehicle-treated APP/
E4 mice failed to demonstrate significant preference
toward the novel object (Figure 1B).
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During RAM testing, WT/E2 mice, and vehicle- and
Aβ12-28P-treated APP/E2 mice showed gradual improvement in performance on consecutive testing days, making
comparable number of errors while navigating through
the maze (Figure 1C). WT/E4 mice and vehicle- and
Aβ12-28P-treated APP/E4 mice also showed gradual
improvement in performance on consecutive days of
RAM testing. However, vehicle-treated APP/E4 mice made
significantly more errors than WT/E4 mice (p < 0.001) and
Aβ12-28P-treated APP/E4 mice (p < 0.001), confirming the
presence of memory impairment in APP/E4 mice at the
age of 10 months (Figure 1D). Aβ12-28P-treated APP/E4
mice showed no significant difference from WT/E4 mice
in the RAM testing, indicative of a therapeutic effect of
apoE4/Aβ binding disruption in vivo.
Analysis of Aβ plaque load

The load of Th-S positive Aβ plaques (percentage of
cross-sectional area of an anatomical structure covered
by the plaques) was quantified in the neocortex and the
hippocampus on serial coronal brain sections. In vehicletreated APP/E4 mice, the load of Th-S-stained plaques in
the neocortex and the hippocampus was 2.6- and 2.9-fold
higher than that in APP/E2 mice (p < 0.0001), (Figure 2A
and B). Aβ12-28P treatment was associated with reduction of Aβ plaque load in the neocortex and the
hippocampus in APP/E2 mice by 41.7% (p < 0.001) and
34.4% (p < 0.05), respectively, while in APP/E4 mice
the reduction was 23.0% (p < 0.01) and 21.7% (p < 0.05),
respectively. As Th-S reveals only fibrillar structure of Aβ
plaques, we also stained serial brain sections with mAb
HJ3.4 directed against the N-terminus of Aβ [13,24].
Differences in the load of Aβ plaque deposits shown by
anti-Aβ immunohistochemistry among APP/E2 and APP/
E4 mice treated with vehicle or Aβ12-28P corresponded
to that revealed by Th-S staining (Figure 2C). A small
number of Aβ deposits associated with brain and meningeal vessels was also seen in APP/E4 mice, however, their
appearance was too sparse and variable from one brain
section to the next to be reliably quantified.
Biochemical analysis of brain Aβ levels

Brain Aβx-40 and Aβx-42 levels (please see The Methods
section for explanation of Aβ peptide nomenclature used
here) were measured following DEA and formic acid FA
extractions, which release soluble Aβ and insoluble Aβ
associated with Aβ plaques and vascular deposits, respectively. Striking differences between vehicle-treated APP/E2
and APP/E4 mice were noted. In APP/E4 mice, soluble
Aβx-40 and Aβx-42 levels were 7.7-fold and 22.5-fold higher
than those in APP/E2 mice (p < 0.0001), respectively; while
insoluble Aβx-40 and Aβx-42 levels were 5.6-fold (p < 0.001)
and 9.2-fold (p < 0.01) higher than those in APP/E2 mice,
respectively (Figure 3A-D). Furthermore, the two lines
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Figure 1 Effects of Aβ12-28P treatment on the performance of APP/E2 and APP/E4 mice during the object recognition (ORT) and radial
arm maze (RAM) tests. Aβ12-28P treatment prevents memory deficit in APP/E4 mice. (A and B) Mean (±SEM) time spent interacting with familiar
and novel objects during the retention session of the ORT (n = 8–12/group). ns: not significant, *** p < 0.01, **** p < 0.001, versus the familiar object
(Student’s t test). (C and D) Mean (±SEM) number of errors per session plotted against testing days on the RAM (n = 7–12/group). (C), ANOVA
p = 0.139. (D), ANOVA p = 0.0002, *** p < 0.001, versus APP/E4vehicle (Newman-Keuls post-hoc test). Age and sex-matched wild-type (WT) littermates of
APOE ε2 and ε4 background (WT/E2, WT/E4) were tested as controls in both tests.

significantly differed in the Aβx-40:Aβx-42 ratio. In APP/E2
mice the level of soluble Aβx-40 was 2.1-fold higher than
that of soluble Aβx-42 (p < 0.0001), while in the APP/E4
mice the opposite relation was observed, with the level of
soluble Aβx-42 being 1.4-fold higher than that of soluble
Aβx-40 (p < 0.05). In APP/E2 mice, levels of insoluble
Aβx-40 and Aβx-42 were similar, while in APP/E4 mice
the level of insoluble Aβx-42 was 1.8-fold higher than
that of Aβx-40 (p < 0.05). In both APP/E2 and APP/E4
mice, insoluble Aβx-40 and Aβx-42 levels were over 15-fold
higher than those of soluble peptides (p < 0.001).
Aβ12-28P treatment was associated with a significant
reduction in levels of soluble Aβx-40 and Aβx-42, which
in APP/E2 mice were reduced by 30.1% (p < 0.001) and
35.8% (p < 0.0001), respectively; while in APP/E4 mice
by 32.1% (p < 0.05) and 38.2% (p < 0.01), respectively
(Figure 3A and B). Levels of insoluble Aβx-40 and Aβx-42
in Aβ12-28P-treated APP/E2 mice were reduced by 44.2%
and 51.8%, respectively (p < 0.0001); while in Aβ12-28Ptreated APP/E4 mice by 30.6% and 33.8%, respectively
(p < 0.05) (Figure 3C and D). Furthermore, we measured
the brains’ content of Aβ oligomers using ELISA, which
utilizes the same mAb as both the capture and detection

antibody, allowing four-member solid phase sandwiches
to be formed only when aggregates containing multiple
Aβ copies are present in the sample. As with other forms
of Aβ, the concentration of Aβ oligomers in vehicletreated APP/E4 mice was 79.2-fold higher than that in
APP/E2 mice (p < 0.001). Aβ12-28P treatment reduced
the level of Aβ oligomers by 46.1% and 23.5% in APP/E2
and APP/E4 mice, respectively (p < 0.001) (Figure 3E).
Analysis of the brain apoE level and its accumulation
within Aβ plaques

Levels of soluble and insoluble human apoE were measured
in brain homogenate extracted with DEA and FA, respectively. There was no significant difference in the level of
soluble apoE between vehicle-treated APP/E2 and APP/E4
mice (Figure 4A). The insoluble apoE level was 2-fold
higher in APP/E4 mice than in APP/E2 mice (p < 0.0001)
(Figure 4B). Aβ12-28P treatment was associated with a
34.1% (p < 0.01) reduction in the soluble apoE level in APP/
E2 mice and a 45.7% reduction in the level in APP/E4 mice
(p < 0.0001). Insoluble apoE levels were reduced with
Aβ12-28P treatment by 41.4% in APP/E2 mice (p < 0.0001)
and by 54.6% in APP/E4 mice (p < 0.0001).
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Figure 2 Analysis of Aβ plaque load. Aβ12-28P treatment reduces
Aβ plaque formation in the neocortex and hippocampus of APP/E2
and APP/E4 mice. (A) Representative microphotographs of thioflavin-Sstained coronal brain sections from vehicle- and Aβ12-28P-treated
APP/E2 and APP/E4 mice at the level of the dorsal hippocampus.
(B) Mean (±SEM) thioflavin-S positive Aβ plaque load in the neocortex
and the hippocampus (n = 7–8/group). * p < 0.05, ** p < 0.01, ***
p < 0.001, vs. vehicle-treated mice of the same APOE background,
(Student’s t test). #### p < 0.0001, vehicle-treated APP/E2 mice vs.
vehicle-treated APP/E4 mice (Student’s t test). (C) Representative
microphotographs of coronal brain sections from vehicle- and
Aβ12-28P-treated APP/E2 and APP/E4 mice showing the hippocampus,
and somatosensory cortex, which were immunostained against the
N-terminus of Aβ. Scale bars 500 μm (A and C).

Furthermore, we quantified the load of apoE-positive
plaque load, which also bound the amyloid dye Th-S.
The load of apoE plaques was 2.9-fold higher in the neocortex (p < 0.0001) and 4.2-fold higher in the hippocampus (p < 0.01) in vehicle-treated APP/E4 mice than in
the corresponding structures of vehicle-treated APP/E2
mice (Figure 4C and D). Aβ12-28P treatment was associated with a 26.9% reduction in the apoE-positive
plaque load in the neocortex (p < 0.05) and a 37.5% reduction in the hippocampus (p < 0.05) in APP/E2 mice,
and with a 49.9% (p < 0.001) and 48.5% (p < 0.05) reduction in the corresponding structures in APP/E4 mice,
respectively.
Neuritic plaques

Neuritic dystrophy associated with Aβ plaques was revealed using the Gallyas silver stain (Additional file 1:
Figure S3 A-E). In APP/E4 mice, the numerical density
of neuritic plaques in the neocortex and the hippocampus was 5.2-fold and 6.5-fold higher than those in the
corresponding structures of APP/E2 mice, respectively
(p < 0.001) (Figure 5A and B). Aβ12-28P treatment reduced the neuritic plaques density in the neocortex and
the hippocampus of APP/E2 mice by 47.1% and 38.5%,
respectively (p < 0.05), while in APP/E4 mice by 48.8%
(p < 0.001) and 43.6% (p < 0.01), respectively.

Discussion
ApoE isoforms differentially modulate Aβ metabolism,
Aβ accumulation, and AD morbidity in human subjects.
We demonstrated here that APOE ε2 and APOE ε4 targeted replacement in APPSW/PS1dE9 AD Tg model mice
reproduces the differential effect of encoded by these alleles apoE isoforms on various aspects of Aβ pathology
and associated neurodegeneration. Ten-month-old APP/
E2 mice showed no behavioral deficit compared to WT/
E2 mice, despite a modest Aβ plaque load and Aβ oligomer level. In contrast, age and sex matched APP/E4
mice revealed a pronounced memory deficit along with
a several-fold higher load of Aβ plaques and insoluble
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Figure 3 Biochemical analysis of Aβ brain levels. Aβ12-28P
treatment reduces soluble and insoluble brain Aβ levels and those
of aggregated Aβ in APP/E2 and APP/E4 mice. Levels of soluble
(diethylamine-extractable) Aβx-40 (A) and Aβx-42 (B) and levels of
insoluble (formic-acid-extractable) Aβx-40 (C) and Aβx-42 (D). (E)
Levels of aggregated Aβ species. All values are mean (±SEM) in
10–12 APP/E2 animals and 7–9 APP/E4 animals. (A-E), * p < 0.05
** p < 0.01, *** p <0.001, *** p <0.0001, versus the vehicle-treated
mice of the same APOE background, (Student’s t test). ## p < 0.01
###
p < 0.001, #### p < 0.0001, vehicle-treated APP/E2 mice vs.
vehicle-treated APP/E4 mice (Student’s t test).

Aβ level, and nearly an 80-fold higher level of Aβ oligomers compared to APP/E2 mice. Oligomeric Aβ species
have been shown to cause memory deficits in rodents
[25] and are known for their synaptotoxic properties. This
synaptotoxicity is associated with a reduction in the
surface expression of various receptor proteins, including those forming the N-methyl-D-aspartate receptors
[26,27], which are critical for generation of long-term potentiation in hippocampal synapses. We also found
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Figure 4 Aβ12-28P treatment reduces soluble and insoluble
brain apoE levels and apoE deposition in Aβ plaques in APP/E2
and APP/E4 mice. Levels of soluble (diethylamine-extractable) human
apoE (A) and those of insoluble (formic-acid-extractable) human
apoE (B). Values are mean (±SEM) in 11–12 animals of APP/E2
background and 8 animals of APP/E4 background. (C) Representative
microphotographs of coronal sections through the sensorimotor
cortex at the level of the posterior caudate-putamen from vehicle- and
Aβ12-28P-treated APP/E2 and APP/E4 mice, which were immunostained
against human apoE. White arrowheads indicate apoE positive deposits.
(D) Mean (±SEM) human apoE positive plaque load in the neocortex
and the hippocampus (n = 7–8/group). (A, B, D) * p < 0.05, ** p < 0.01,
*** p < 0.001, *** p < 0.0001, versus vehicle-treated mice of the same
APOE background (Student’s t test). ## p < 0.01, #### p < 0.0001,
vehicle-treated APP/E2 mice vs. vehicle-treated APP/E4 mice (Student’s
t test). Scale bar 200 μm (C). Abbreviations: cc, corpus callosum; CPu,
caudate-putamen; NCtx, neocortex.
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Figure 5 Aβ12-28P treatment prevents neuritic degeneration
in APP/E2 and APP/E4 mice. (A) Representative microphotographs
of coronal sections through the sensorimotor cortex at the level of
the posterior caudate-putamen from vehicle- and Aβ12-28P-treated
APP/E2 and APP/E4 mice stained with the Gallyas silver method.
Black arrowheads indicate neuritic plaques revealed by the silver
staining. (B) Mean (±SEM) of the numerical density of Gallyas-positive
neuritic plaques in the neocortex and the hippocampus (n = 7–8/
group). (B) * p < 0.05, ** p < 0.01, *** p < 0.001, versus vehicle-treated
mice of the same APOE background (Student’s t test). ### p < 0.001,
vehicle-treated APP/E2 mice vs. vehicle-treated APP/E4 mice (Student’s
t test). Scale bar 200 μm.

evidence for a differential effect of apoE2 and apoE4 isoforms on Aβ metabolism in APPSW/PS1dE9 mice. APP/E4
mice had significantly higher levels of soluble Aβ peptides
than APP/E2 mice. In particular, the level of soluble Aβx-42,
which is considered more toxic and aggregation prone than
Aβx-40, was 22.5-fold higher in APP/E4 mice than in APP/
E2 mice. Furthermore, in APP/E2 mice, the soluble Aβx-40
level was 2.1-fold higher than that of Aβx-42, while in APP/
E4 the ratio was reversed, with the level of soluble Aβx-42
being 1.4-fold higher than that of Aβx-40. These striking differences in the brain levels of soluble Aβx-40 and Aβx-42
peptides, and the reversed ratio, between APP/E2 and APP/
E4 mice are likely related to the well-established differential
effect of apoE2 and apoE4 isoforms on Aβ brain clearance
[28]. Increased soluble Aβ levels and a predominance of
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Aβx-42 associated with the apoE4 isoform, produce a background promoting greater Aβ deposition and enhanced
neurodegeneration. In fact, the load of Th-S positive Aβ
plaques and the brain concentration of insoluble Aβ,
which are associated with fibrillar Aβ deposits, were
several-fold higher in APP/E4 mice than in APP/E2 mice.
Enhanced Aβ deposition was, in turn, associated with a
greater degree of neurodegeneration, as demonstrated by a
several-fold higher density of neuritic plaques in APP/E4
animals as compared to APP/E2 animals. APOE ε4 targeted
replacement was also associated with significantly greater
co-deposition of apoE in Aβ plaques, as shown by the comparison of apoE-positive plaque load and the level of insoluble apoE between APP/E4 and APP/E2 mice. It has been
previously demonstrated that co-deposition of apoE in
Aβ plaques is a prerequisite for the occurrence of focal
neuritic dystrophy [22,29].
Epidemiological evidence and evidence from neuropathological assessment of the impact of apoE isoforms
on the brain Aβ load, have suggested that apoE2 exerts a
protective effect against Aβ pathology and AD morbidity
[3,9,10], while apoE4, in contrast, markedly enhances the
disease process [7,8,30]. To directly examine whether
apoE2 exerts a truly “therapeutic” effect or, on the contrary,
is involved in promoting Aβ deposition, we systemically
treated APP/E2 mice with Aβ12-28P, which disrupts the
apoE/Aβ binding. Another objective of this study was to
investigate whether an apoE/Aβ binding inhibitor would
ameliorate Aβ pathology and associated neurodegeneration,
as shown in an exaggerated form by the apoE4 isoform.
We demonstrated that Aβ12-28P treatment produced
significant reductions in the Aβ oligomer level, the Aβ
plaque load, and the concentration of insoluble Aβ peptides, and ameliorated the neurodegenerative component
of Aβ plaques in both APP/E2 and APP/E4 mice. These
observations provide clear in vivo evidence that both
apoE2 and apoE4 isoforms are involved in the process of
Aβ aggregation and deposition and are associated with
neurodegeneration, although the effect of apoE4 appears
to be much stronger than that of apoE2. Our findings
remain consistent with the effects of apoE knock-out
noted in several AD Tg mouse models, where lack of apoE
was associated with absence of fibrillar Aβ deposits and
prevented neurodegeneration [13,29,31,32]. In addition to
a marked reduction in Aβ deposition in Aβ12-28P-treated
mice, we also noticed a significant reduction in the
level of Aβ oligomers. It has been recently appreciated
that apoE, especially its apoE4 isoform, facilitates the
formation of Aβ oligomers [33,34]. Although it appears
that enhanced Aβ oligomerization occurs in settings of
elevated Aβx-42 level, which is associated with the apoE4
background, there is experimental evidence to indicate
that direct interaction between apoE and Aβ facilitates Aβ
oligomeric assembly and that all three isoforms promote
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this process in the rank order E4 > E3 > E2 [33]. Reduced
Aβ oligomer level following from disrupted apoE/Aβ
binding appears to provide further evidence that the
direct apoE/Aβ interaction enhances oligomeric assembly
of Aβ and that treatment with an apoE/Aβ inhibitor is
beneficial for preventing Aβ oligomerization and for
ameliorating synaptotoxicty related to Aβ oligomers.
Furthermore, we observed that along with reducing Aβ
deposition, Aβ12-28P treatment also ameliorated apoE
accumulation in the brain. It has been proposed that
co-deposition of apoE with Aβ is an important factor
promoting fibrillization of Aβ and plaque formation
[22,23]. It has also been recognized that co-deposition
of apoE in Aβ plaques promotes focal neurodegeneration
in humans and in AD Tg mice [22,29,35]. Reduction of
apoE deposition in Aβ12-28P-treated mice demonstrates
an additional mechanism through which disruption of the
apoE/Aβ interaction may ameliorate Aβ plaque formation
and associated neurodegeneration. Similarly, it has
been shown that Aβ accumulation in the brain of
APPSW/PS1dE9 mice can be effectively reduced through
targeting brain apoE with systemic anti-apoE passive
immunization [36].
Clearance of soluble Aβ from the brain is critical in
preventing its accumulation and there is evidence this
process can be differentially regulated by apoE isoforms
[28]. Several studies have shown that the bulk of soluble
Aβ is cleared through its direct interaction with the LDL
receptor family expressed by brain capillary endothelium
[37], neurons [24,38], and astrocytes [39,40], therefore
pharmacological disruption of the apoE/Aβ binding is
unlikely to impair this process. What is more, since some
of Aβ forms complexes with apoE [41], an apoE/Aβ antagonist can free up this apoE bound Aβ increasing soluble
Aβ pool and promoting its clearance. It has been also
proposed that apoE can indirectly modulate Aβ clearance
through competing with Aβ for the same receptors [40].
This notion may explain enhanced Aβ clearance in the
setting of apoE2, which is defective in LDL receptor binding [4,5]. Since we observed reduced levels of soluble apoE
in Aβ12-28P-treated APP/E2 and APP/E4 mice, the treatment with an apoE/Aβ inhibitor may additionally facilitate
Aβ clearance by reducing the levels of apoE competing
with Aβ for the same receptor clearance pathway. In fact,
in our study levels of soluble Aβx-40 and Aβx-42 peptides
were significantly reduced in both Aβ12-28P-treated APP/
E2 and APP/E4 mice providing evidence that the apoE/Aβ
binding antagonist may enhance soluble Aβ clearance.
The accumulation of Aβ in the brain is considered to
be a prime target of disease-modifying therapies for AD
[2]. Although clinical trials of the Aβ-directed mAb
Bapinezumab showed no clear cognitive benefits in
patients with mild to moderate AD [42], the results also
indicated that APOE ε4 carrier status may limit the
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response to anti-Aβ passive immunization [43,44], as well
as being associated with an increased rate of microbleeds
and vasogenic edema [45]. As the intention of upcoming
clinical trials of Aβ-directed therapeutics is to target
patients with early and prodromal AD [46,47], there is
still a potential for differential responses to treatment
among carriers of various APOE alleles. Our study provides
evidence for efficacy of an agent disrupting the apoE/Aβ
interaction in the setting of apoE2 and apoE4 isoforms.
Therefore, such an agent could be applied in human populations diversified by apoE isoform status. Furthermore, as
apoE/Aβ binding inhibitors would primarily target apoE
promoting effect on Aβ assembly and deposition, they have
the potential to be combined for additive efficacy with other
Aβ-targeting strategies still under development, including
β-secretase inhibitors and γ-secretase modulators inhibiting
Aβ production, or with passive immunization, which promotes Aβ clearance from the brain and stimulates plaque
clearance by microglia [48,49]. Results of this study justify
efforts to develop clinically viable, small-molecule inhibitors
of the apoE/Aβ interaction and test their therapeutic
application, either as a monotherapy or in conjunction
with other anti-Aβ approaches.
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